Tadalafil Tablet
Product Images NDC 68788-4018

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68788-4018). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tadalafil Tab 5mg (20mg Dahej 30s)

Label for Tadalafil Tab 5 mg, a prescription oral tablet generic for Cialis, manufactured by Torrent Pharmaceuticals Limited and labeled by Preferred Pharmaceuticals Inc. The label includes dosing instructions in English and Spanish, storage warnings, and a barcode. Tablets are yellow, oval, and imprinted with B1/5.*

FDA Label Image

Structural Formula (30ee4705 36a5 4a56 852d 9d76c40668db 01)

Chemical structure of tadalafil, the active ingredient in the oral tablet prescription drug TADALAFIL by Preferred Pharmaceuticals Inc. This structure depicts the molecular arrangement of tadalafil's atoms and bonds.*

FDA Label Image

Figure 1 (30ee4705 36a5 4a56 852d 9d76c40668db 02)

A set of four line charts comparing the differences in standing and supine systolic and diastolic blood pressures (mmHg) between tadalafil and placebo over time in hours. The charts display mean values with error bars for each time point from 0 to 96 hours, showing blood pressure differences trending around zero or slightly negative for tadalafil relative to placebo.*

FDA Label Image

Figure 2 (30ee4705 36a5 4a56 852d 9d76c40668db 03)

A line graph showing the effects of Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg on standing and supine systolic blood pressure over 24 hours post-dose. The y-axis represents change in systolic BP (mmHg), and the x-axis represents time (hours) post-dose, with two curves comparing blood pressure changes for each treatment group.*

FDA Label Image

Figure 3 (30ee4705 36a5 4a56 852d 9d76c40668db 04)

A line graph depicting the change in systolic blood pressure (mmHg) over 12 hours after administration of 20 mg tadalafil or placebo, each combined with 8 mg doxazosin at 08:00 or 20:00. The chart shows four data series tracking blood pressure changes at different dosing times and treatments.*

FDA Label Image

Figure 4 (30ee4705 36a5 4a56 852d 9d76c40668db 05)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing conditions: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose after 5 consecutive days of administration. The graph plots concentration on the vertical axis and time on the horizontal axis, including error bars for variability.*

FDA Label Image

Figure 5 (30ee4705 36a5 4a56 852d 9d76c40668db 06)

A line graph showing the change from baseline in IPSS total score over 12 weeks of treatment comparing Tadalafil 5 mg and placebo. The x-axis represents duration of treatment in weeks, and the y-axis shows change from baseline in score. Tadalafil 5 mg shows a greater decrease in score compared to placebo, with a statistically significant difference indicated at 12 weeks.*

FDA Label Image

Figure 6 (30ee4705 36a5 4a56 852d 9d76c40668db 07)

A line graph comparing the change from baseline in IPSS Total Score over a 12-week treatment duration for Tadalafil 5 mg versus placebo. The x-axis represents the duration of treatment in weeks, while the y-axis shows the change from baseline in score. Tadalafil shows a greater reduction in score compared to placebo, with statistically significant differences marked.*

FDA Label Image

Figure 7 (30ee4705 36a5 4a56 852d 9d76c40668db 08)

A line graph showing the least-squares mean change from baseline over 26 weeks of therapy for two groups: Tadalafil/Finasteride and Placebo/Finasteride. The Y-axis represents LS mean change from baseline, decreasing from 0.0 to -7.0. The X-axis shows weeks of therapy at 0, 4, 12, and 26 weeks. The graph includes markers for statistical significance (p-values) at various points on the timeline.*

FDA Label Image

Figure 8 (30ee4705 36a5 4a56 852d 9d76c40668db 09)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment with Tadalafil 5 mg versus placebo. The x-axis shows treatment duration in weeks (0, 2, 4, 8, 12), and the y-axis shows change from baseline scores. The graph indicates greater score improvement with Tadalafil 5 mg compared to placebo, with statistically significant difference marked at 12 weeks (p<0.01).*

FDA Label Image

Torrent Logo (30ee4705 36a5 4a56 852d 9d76c40668db 10)

FDA Label Image

Torrent Logo-pi (30ee4705 36a5 4a56 852d 9d76c40668db 11)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.